Objective-To test the therapeutic activity of perivascular transplantation of encapsulated human mesenchymal stem cells (MSCs) in an immunocompetent mouse model of limb ischemia. Approach and Results-CD1 mice underwent unilateral limb ischemia, followed by randomized treatment with vehicle, alginate microbeads (MBs), MB-encapsulated MSCs (MB-MSCs), or MB-MSCs engineered with glucagon-like peptide-1. Treatments were applied directly in the perivascular space around the femoral artery. Laser Doppler and fluorescent microsphere assessment of blood flow showed a marked improvement of perfusion in the MB-MSCs and MB-MSCs engineered with glucagon-like peptide-1 groups, which was associated with increased foot salvage particularly in MB-MSCs engineered with glucagon-like peptide-1-treated mice. Histological analysis revealed increased capillary and arteriole density in limb muscles of the 2 MSC groups. Furthermore, MB-MSCs engineered with glucagon-like peptide-1 and, to a lesser extent, MB-MSC treatment increased functional arterial collaterals alongside the femoral artery occlusion. Analysis of expressional changes in ischemic muscles showed that MB-MSC transplantation activates a proangiogenic signaling pathway centered on vascular endothelial growth factor A. In contrast, intramuscular MB-MSCs caused inflammatory reaction, but no improvement of reparative vascularization. Importantly, nonencapsulated MSCs were ineffective either by intramuscular or perivascular route. Conclusions-Perivascular delivery of encapsulated MSCs helps postischemic reperfusion. This novel biological bypass method might be useful in patients not amenable to conventional revascularization approaches.
P eripheral artery disease (PAD) affects up to 15% of people >55 years. 1 Critical limb ischemia (CLI) is the end stage of lower extremity PAD in which severe obstruction of blood flow results in ischemic rest pain, ulcers, and high risk for limb loss. Surgical bypass surgery or percutaneous revascularization, the gold standard for the treatment of PAD, produces long-term benefit with a 5-year limb salvage rate of >80%. 2 However, ≈30% of patients with CLI cannot be revascularized because of multivascular disease or occlusions of small-caliber blood vessels, which are common in patients with diabetes mellitus and hypertension. 3 Gene and stem cell therapies have been accredited to provide a possible alternative to interventional angioplasty. 4, 5 Clinical trials using bone marrow-derived mononuclear cells showed significant benefit, including improvement of ankle brachial index, transcutaneous partial pressure of oxygen, reduction of pain, and decreased need for amputation. [6] [7] [8] [9] Intramuscular, intra-arterial injection, or a combination of both represents the preferred route of cell therapy in clinical trials. Both the methods have limitations depending on the disease pattern. Intraarterial infusion is not ideal for patients with occluded femoral artery because the stem cells will not reach the affected site by blood flow, whereas intramuscular delivery requires multiple injections to maximize the extension of therapeutic benefit. In BONe Marrow Outcomes Trial 1&2 (BONMOT-1&2), injections were placed instead along the occluded arteries with the intention to increase the formation of collaterals bypassing the occlusion. 10 A common drawback of the above methods is that cell retention is generally low because of massive apoptosis in the first few days after implantation. Microencapsulation strategies, surrounding the cells with a semipermeable polymeric membrane, have been proposed for enhancing cell viability. [11] [12] [13] [14] Here, the aim is to use the cells as local drug delivery factories, to secrete a cocktail of beneficial factors to elicit a therapeutic paracrine effect. Recently, we have developed a novel miniaturized encapsulation procedure where stem cellcontaining corebeads are surrounded with a permeable shell of biocompatible alginate, which provides a robust immunoisolating barrier, whereas allowing for diffusion of inherent paracrine factors, such as vascular endothelial growth factor (VEGF). 15 Furthermore, the optimized shell-to-core ratio ensures full cell viability. This new formulation (CellBeads) contains human mesenchymal stem cells (MSCs) genetically modified to express glucagon-like peptide-1 (GLP-1), an incretin hormone that has antiapoptotic, proangiogenic, and cardioprotective effects. [16] [17] [18] [19] Intracoronary injection of CellBeads passed feasibility and safety tests and showed therapeutic benefit in a porcine model of acute myocardial infarction. 20, 21 In addition, CellBeads have been evaluated in a clinical study to treat patients with posthemorrhagic stroke to limit the ensuing apoptotic damage. 22 Based on these encouraging data, we propose that CellBeads might be used as an off-the-shelf cell product for wide-scale treatment of CLI.
Therefore, in view of clinical application, the present study investigates the feasibility of CellBead delivery into the perivascular space surrounding the occluded femoral artery and the efficiency of CellBead transplantation in improving reparative angiogenesis and collateralization in an immunocompetent mouse model of limb ischemia.
Results

Feasibility of Perivascular Cell Delivery
To assess the retention of microbeads (MB), cryosections from en bloc muscle samples were collected at day 7 after ischemia induction. Hematoxylin and eosin staining of these samples demonstrated the presence of MB-MSCs engineered with GLP-1 (MB-MSC-GLP) surrounding the femoral artery and vein, thus, confirming the feasibility of the procedure ( Figure 1A ). Furthermore, cell-transplanted muscles showed increased capillary (P<0.02 versus vehicle) and arteriole density (P<0.05 versus vehicle) at the site of implantation ( Figure 1B-1D ). Arterioles were oriented coaxially with the femoral artery.
Improvement of Clinical Outcomes
Limb salvage (no necrotic toe) occurred in 33% and 42% of mice given vehicle or MB, respectively. This outcome was improved by MSC transplantation, with 66% salvage in MB-MSC and 75% in MB-MSC-GLP-treated groups. Global clinical outcome considering the number of mice with ≥1 necrotic toes or foot necrosis/amputation is illustrated in Figure 2A . Analysis of contingency by the χ 2 test was not applicable because the data set comprised several values <1, and <20% of the values were >5. Therefore, an arbitrary score from 0 (no necrosis) to 6 (foot necrosis/ amputation) was computed and used to compare the experimental groups. ANOVA detected a difference among groups pertaining to the severity score (P<0.01). MB-MSC-GLPtreated mice showed the lowest severity score (0.4±0.3; P<0.01 versus vehicle and P<0.05 versus MB), followed by MB-MSC (1.2±0. 
Improvement of Perfusion
Laser Doppler blood flow recovery was different among groups (2-way ANOVA, group effect: P<0.0001). Bonferroni multiple comparison analysis indicates an improvement of blood flow in MB-MSC-GLP-and MB-MSC-treated groups (P<0.001 versus vehicle or MB from day 7 to day 21; Figure 2B ). Cohen d coefficient indicates that the biological effect of MB-MSC-GLP and MB-MSC treatments is large (2.8 and 2.4 versus vehicle and 2.0 and 1.9 versus MB, respectively). In contrast, no difference was observed between MB-MSC and MB-MSC-GLP groups.
Analysis of blood flow to the adductor muscle at 21 days postischemia using fluorescent microspheres indicates a significant difference among groups (ANOVA, group effect: P=0.02), with the MB-MSC-GLP group showing a large improvement compared with vehicle (P<0.01; Cohen d coefficient, 2.6) or MB (P<0.05; Cohen d coefficient, 1.9; Figure 2C ). Moreover, the MB-MSC group showed higher blood flow levels compared with vehicle (P<0.05; Cohen d coefficient, 1.9). No difference was detected between MB-MSC and MB-MSC-GLP treatments. Moreover, no group difference was observed in perfusion of contralateral adductor.
Similarly, Po 2 levels in the ischemic adductor were markedly improved in the MB-MSC-GLP-or MB-MSC-treated groups compared with vehicle or MB (ANOVA, P<0.0001; Figure 2D ). The effects in both treatment groups can be considered very large (Cohen d coefficient, 3.7 and 3.4, respectively). 
Promotion of Reparative Angiogenesis
Immunofluorescence microscopy showed a significant increase in the number of capillaries in ischemic adductor muscles of MB-MSC-transplanted mice (879±16 capillaries/mm 2 ) compared with vehicle (673±13 capillaries/mm 2 ; P<0.001; Figure 3A ). Similarly increased were small arterioles (15.3±0.5 versus 9.1±0.3 arterioles/mm 2 in vehicle; P<0.001; Figure 3B ). Analogous improvements were observed in the MB-MSC-GLP-treated group (891±20 capillaries/mm 2 and 14.6±0.8 arterioles/mm 2 ; P<0.001 versus vehicle for both comparisons; Figure 3A and 3B). The effect of MB-MSC and MB-MSC-GLP treatments on neovascularization was very large (Cohen d coefficient, 5.5 and 5.0 for capillaries and 6.5 and 3.6 for arterioles, respectively). Use of MB alone did not produce any improvement (736±13 capillaries/mm 2 and 10±0.5 arterioles/mm 2 ; P=NS versus vehicle; Figure 3A and 3B).
Collateral Formation Along the Occluded Artery
Cell therapy approaches mainly enhance the microvasculature downstream to the vascular occlusion. However, unless the artery blockage is removed or bypassed, it is unlikely that the increased microvascular bed will restore optimal perfusion. We verified whether the increased muscular blood flow and oxygenation observed in our study was associated with an increased collateralization along the femoral artery, and whether these collaterals were functionally operative. We found that MB-MSC-GLP-and MB-MSC-treated mice have an increased number of capillaries (460±12 and 389±23 versus 177±10 capillaries/mm 2 in vehicle; P<0.001; Figure 3C ), small arterioles (10.3±0.3 and 9.0±0.4 versus 5.7±0.2 arterioles/mm 2 in vehicle; P<0.01; Figure 3D ), and large arterioles (4.0±0.2 and 3.6±0.2 versus 2.2±0.2 arterioles/mm 2 in vehicle; P<0.01; Figure 3D ) in the implant site around the arterial occlusion. The effects induced by MB-MSC-GLP and MB-MSC treatments were very large (Cohen d coefficient: 10.8 and 4.8 for capillaries, 7.6 and 4.7 for small arterioles, and 4.1 and 3.2 for large arterioles, respectively). Interestingly, pairwise comparison indicates that MB-MSC-GLP is superior to MB-MSC treatment in increasing capillary and small arteriole density (P<0.05 for both comparisons; Cohen d coefficient, 1.5 and 1.6 for capillaries and arterioles, respectively). Treatment with MB did not affect local vascularization (218±4 capillaries/mm 2 , 5.3±0.6 small arterioles/mm 2 and 2.3±0.3 large arterioles/mm 2 ; P=NS versus vehicle).
To verify the functional status of periocclusional vascularization, whole-mount preparations of the implantation site were analyzed after intravenous injection of the endothelial marker isolectin. Three-dimensional reconstruction of confocal microscopy images showed numerous functional capillaries and arterioles bridging the space between implanted MB-MSC-GLP and MB-MSC and the ischemic muscles ( Figure 4 ; Movie I in the online-only Data Supplement).
Activation of Angiogenic Factors
To verify the mechanisms for improved angiogenesis, we measured gene and protein expression in limb muscles at 7 days after ischemia.
Results of cytometric bead arrays show the expression of human angiogenic proteins in ischemic muscles of MB-MSC-and MB-MSC-GLP-treated mice ( Figure 5 ), indicating persistence of paracrinally active human cells. Furthermore, RT-profiler polymerase chain reaction array showed a marked activation of murine genes associated with angiogenesis, such as endoglin, VEGF-A, sphingosine kinase 1, angiopoietin 4, interleukin-8, and heparanase, in ischemic muscles of MB-MSC-and MB-MSC-GLP-treated mice compared with vehicle (Table) . Notably, the 2 treatments markedly reduced the expression of β2-microglobulin, which is a biomarker of peripheral vascular disease, 23 as well as the expression of several antiangiogenic genes, such as tissue inhibitor of metalloproteinase 2, tissue inhibitor of metalloproteinase 3, and thrombospondin 2, and proinflammatory genes associated with T lymphocytes induction of MSC apoptosis, including interferon-γ and tumor necrosis factor-α. Moreover, quantitative polymerase chain reaction confirmed the expression of the GLP transgene in limb muscles injected with MB-MSC-GLP ( Figure III in the onlineonly Data Supplement).
The interaction of differentially regulated genes was then investigated using the STRING database ( Figure 6 ). Results indicate that transplantation of MB-MSCs interferes with a molecular network centered on VEGF-A, interleukin-6, interferon-γ, and tumor necrosis factor-α, leading to changes in the balance between angiogenic mediators (the chemokines CXCL3 and CCL2/MCP1, the membrane glycoprotein endoglin, and the S1P activator sphingosine kinase 1), stabilizers of vascular growth (angiopoietin 4 and thrombospondin 1), and enzymes implicated in activation (heparanase) or inhibition (tissue inhibitor of metalloproteinases) of extracellular matrix degradation.
Importance of Cell Delivery Route and Encapsulation
Next, we evaluated the benefit of direct transplantation of encapsulated MSC in ischemic muscles. Intramuscular delivery of MB-MSCs was ineffective in improving the blood flow recovery or muscular capillary density in immunocompetent mice with limb ischemia ( Figure IVA and IVB in the onlineonly Data Supplement). Furthermore, bead injection caused distortion of the muscle structure ( Figure IVCi and IVCii in the online-only Data Supplement) and marked infiltration of inflammatory cells expressing isolectin and the macrophage/ monocyte marker F4/80 (Figure IVCiii-IVCvi in the onlineonly Data Supplement). Therefore, perivascular delivery of the current CellBead formulation seems to be superior to intramuscular injection.
In separate experiments, we evaluated the therapeutic activity of perivascular or intramuscular transplantation of nonencapsulated MSCs. In both cases, allogeneic cell therapy was unable to produce improvement of blood flow recovery in immunocompetent mice with limb ischemia ( Figure VA To verify whether the lack of therapeutic activity is related to the rapid clearance of cells that are not protected by an immunoisolating shell, we next measured the expression of human angiogenic proteins in mice given nonencapsulated MSCs (either intramuscularly or perivascularly) or vehicle. Human proteins were undetectable in ischemic murine muscles from all studied groups. These data suggest functional inactivation of nonencapsulated MSCs at 7 days from transplantation in perivascular or interstitial muscular space.
Discussion
This study is the first to show the therapeutic activity of a cell product consisting of encapsulated, genetically modified MSCs, which were delivered perivascularly in a mouse model of limb ischemia. On stabilization at the implantation site, the cell product induces microvascular angiogenesis in the ischemic muscle as well as collateralization alongside the occluded femoral artery, leading to restoration of perfusion, oxygenation, and remarkable improvement of limb salvage. The therapeutic effect is mainly attributable to paracrine modulation of a molecular network in which VEGF-A represents the central hub.
The originality in the design of CellBeads consists of a miniaturized 2-step encapsulation, which is critical for the product (unpublished data). Furthermore, the novel approach described here combines several implementations of cell therapy in 1 single cell product. The CellBeads formulation enables long-lasting cell retention in the transplanted site and integrates the native paracrine activity of MSCs with a genetic modification conferring encapsulated cells with the ability to produce and secrete GLP-1, an incretin hormone that has both antiapoptotic and cytoprotective effects. 24 Delivery of MB-MSC-GLP alongside the occluded femoral artery allows for authentic stimulation of collateralization together with potentiation of muscular vascularization. Individual elements of this approach proved to benefit postischemic angiogenesis. For instance, cell therapy with bone marrow-derived MSCs reportedly improves limb function, reduces the incidence of autoamputation, and attenuates muscle atrophy in a mouse model of limb ischemia. 25 Moreover, MSCs promote lower limb perfusion and foot ulcer healing in patients with CLI, either given alone 26 or in combination with endothelial progenitor cells. 27 MSCs engineered with growth factors or antiapoptotic agents, including Akt, 28 adrenomedullin, 29 and angiopoietin, 30 showed incremental enhancements of therapeutic activity in models of ischemia. Likewise, intracoronary delivery of GLP-1-overexpressing MSCs induces substantial cardiac recovery in an acute myocardial infarction model. 20 Furthermore, the BONMOT-1&2 trials showed the feasibility and advantage of perivascular delivery of dispersed stem cells in CLI. 10 Rapid inactivation of transplanted cells occurs, however, in an allogeneic setting, as documented by the present study. Encapsulation of human MSCs prevents this phenomenon, thus providing a potential means of treating patients with severely debilitating CLI with a single off-theshelf cell product.
Table. Modulation of Pro-and Antiangiogenic Genes in MB-MSC-and MB-MSC-GLP-Treated Groups Compared With the Vehicle as Measured by the RT-Profiler PCR Angiogenesis Array
All the above concepts were integrated in the strategy of delivering immunoprotected MSCs to the vascular occlusion site. Our study shows for the first time that the procedure is feasible and therapeutically useful. Data highlight the additional benefit from 1 particular manifestation of the CellBead technology, whereby MSCs have been genetically modified to secrete a GLP-1 fusion protein. The GLP-1-enriched cell product showed superior foot-salvaging and collateral-forming capacities as compared with MB-MSCs. After arterial occlusion, preexisting vessels start enlarging through an arteriogenic process that is mainly triggered by increased shear stress, but also involves soluble factors, inflammatory cells, cell proliferation, and the remodeling of the extracellular matrix. We found that the arteriogenic process is enhanced by MB-MSC-GLP and, to a lesser extent, by MB-MSCs, most likely through secreted factors that are released into the surrounding environment in the immediate vicinity of the occluded artery. The method used in this study advantageously direct GLP-1 and other native growth factors to the anatomic region where collateralization is maximally desirable, resulting in a robust neovascularization of arterioles coaxially oriented with the femoral artery. This represents a significant improvement over conventional intramuscular cell therapy, which disperses cells and therapeutic mediators in an unpredictable manner. 24 In addition, perivascular delivery of MB-MSC-GLP enhanced the tributary microvascular bed in hindlimb muscles, as documented by increased counts of capillaries and small arterioles in the ischemic adductor. Measurement of human protein expression confirms that CellBeads are secreting proangiogenic factors at day 7 postimplantation, and this is accompanied by an upregulation of murine proangiogenic genes and corresponding downregulation of antiangiogenic genes. The functional improvements in the model are, therefore, likely to arise from a combination of direct effects of the beneficial secretion of proteins, such as VEGF-A from the CellBeads (which is highly conserved and, therefore, active in mouse), together with additional modulation of gene expression in the tissues local to the implant site by the secreted paracrine factors. These factors might reach the skeletal muscle by diffusion through the interstitium or via the expanded collaterals. Therefore, the method allows for additively advantageous implementation of proximal collateralization and distal microvascular angiogenesis.
The present CellBead formulation does not seem to be suitable for intramuscular delivery as benefits of cell therapy are overwhelmed by spatial restriction and excessive inflammatory reaction in the mouse muscle in this model. Studies in large animal models are necessary to compare feasibility and therapeutic activity of direct intramuscular injection versus delivery around the neurovascular femoral bundle.
In summary, the described methodology using microCell-Bead technology may offer potential as a treatment for peripheral vascular disease, whereby administration of multiple microCellBead depots within the vicinity of diseased vessels could promote revascularization and re-established blood flow to the ischemic limb. The approach is particularly attractive for use in patients in whom interventional revascularization is not amenable because of multiple or distal obstructions. Moreover, perivascular cell therapy might be used as an adjuvant treatment in conjunction with or preparation to operative revascularization.
Conclusions
After femoral arterial ligation in a mouse, application of CellBeads in the perivascular space enhances collateralization and neoangiogenesis through secretion of a variety of paracrine factors that may act directly as well as indirectly by inducing the upregulation of proangiogenic chemokines and downregulation of antiangiogenic genes. Functional neovascularization made by capillaries and small-medium size arterioles is significantly enhanced around the site of administration. This leads to significantly improved blood flow, increased tissue oxygenation, and reduced toe necrosis. These results demonstrate the potential for CellBead technology in the treatment of peripheral vascular disease.
Surgical bypass surgery or percutaneous revascularization is the gold standard for the treatment of peripheral vascular disease, producing long-term benefit, with a 5-year limb salvage rate of >80%. Gene or stem cell therapies have accredited to provide a possible alternative to surgical bypass surgery in patients with multivascular disease or occlusions of small-caliber blood vessels, which are commonly seen in those with diabetes mellitus or hypertension. However, the mode of cell delivery for optimal revascularization is highly debatable. The new methodology of administration of multiple microCellBead depots within the vicinity of the diseased vessels as described in this study could be attractive for use in these patients to promote revascularization and re-establish the blood flow to the ischemic limb. Moreover, perivascular cell therapy might be used as an adjuvant treatment in conjunction with or preparation to operative revascularization.
